Inactive Instrument

Pharmacyclics, Inc. Share Price

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
21/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
21/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
08/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
05/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
05/03/15	Wall Street closes up slightly ahead of jobs report	RE
05/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

07/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
07/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
07/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
07/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

05/03/15	Wall Street se reprend un peu dans un climat d'attente
05/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	31/01/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.44%	+1.41%	+4.36%	+10.81%	50.61B
REVOLUTION MEDICINES, INC.	-1.57%	-3.18%	+383.82%	+593.37%	39.11B
IQVIA HOLDINGS INC.	-0.14%	+0.77%	+27.49%	-5.50%	34.64B
BEONE MEDICINES AG	+1.76%	-1.78%	+21.44%	+53.38%	33.79B
CELLTRION, INC.	-0.06%	-0.45%	+2.94%	+28.70%	26.89B
ASCENDIS PHARMA A/S	-1.93%	-1.01%	-	-	16.47B
MEDPACE HOLDINGS, INC.	-1.49%	-6.18%	+63.89%	+120.53%	15.14B
EUROFINS SCIENTIFIC SE	+0.78%	+1.16%	+14.69%	+17.32%	13.85B
ICON PUBLIC LIMITED COMPANY	-0.97%	-2.83%	+10.35%	-33.29%	12.72B
Average	-0.35%	-1.49%	+66.12%	+98.16%	27.02B
Weighted average by Cap.	-0.17%	-1.08%	+80.66%	+122.51%